2 completed, 1 withdrawn. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Type II Diabetes: new trials by email Literature Review of Type II Diabetes trials Research Report on Type II Diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients PAZ320, Placebo - Type II Diabetes | Phase 2 | Withdrawn | Boston Therapeutics | 2012-09-01 | 2020-09-29 | |
| Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 Placebo, Sitagliptin, LEZ763 - Type II Diabetes | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 220 | 2012-03-01 | 2020-12-17 |
| Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes AZD1656, Placebo - Type II Diabetes | Phase 2 | Completed | AstraZeneca | 20 | 2009-02-01 | 2012-12-06 |
Diabetes Mellitus, Type 2 (3) · Diabetes Mellitus (1)
Endocrine System Diseases (3) · Glucose Metabolism Disorders (3) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Diabetes Mellitus (2)
AZD1656 (1) · PAZ320 (1) · Sitagliptin Phosphate (1) · galactomannan (1)
AstraZeneca (1) · Boston Therapeutics (1) · Novartis Pharmaceuticals (1)
United States (2) · France (1)